Today’s collaboration announcement between @MayoClinic and @Merck matters to me because it reflects how we’re rethinking drug discovery and precision medicine.
@MayoClinicPlatform
Congratulations to Dr @SamirPatelMD, our colleague @MayoClinic Arizona, Dr. Ma, and our friends at MDACC for this important work demonstrating the value of proton therapy in oropharyngeal cancer. @MayoCancerCare@MayoRadOnc@MDAndersonNews
https://t.co/6WpeHRN6Sh
Great to have @lauren_henke and @APrice_BeamOn share their expertise and experience with MRI and CBCT-based online adaptive radiation therapy with our department. @MayoRadOnc
Congratulations to our AI team for winning TWO #VIBEsummit awards for their work developing tools detect prostate cancer recurrence and reduce provider burden with automated daily summaries and trial matching. So proud of this incredible team! @MayoRadOnc@MayoCancerCare
Of 3300 physicians and scientists, Dr Paul Brown, my colleague and mentor, was recognized as one of three clinicians of the year at Mayo Clinic Rochester 400+ publications, 4-time teacher of the year, mentor to countless trainees, and dedicated and compassionate clinician
🚨Life update🚨
Absolutely thrilled to announce that I have the privilege of staying on as faculty at @MayoRadOnc next year!
All because of you, Mom ❤️
Grateful for my heme & peds supporters @n_laack@wgbreen@AnitaMahajanMD @ScottLesterMD @RomanKowalchuk
Our own Dr Sharifzadeh’s work on direct-to-unit simulation and adaptive SBRT highlighted in the ASTRO news today. Excellent local control and outcomes while improving access for those at a distance from radiation care @MayoRadOnc @MayoCancerCare
#ASTRO25 SCAROP meeting. Good turnout.
Interesting lineup from most junior as Chair to most senior. A number of chairs >15 years and counting.
Nice to hear from some of the innovators and those helping push field forward.
Too many to tag
Congrats to @DavidRoutmanMD@KatieVanAbelMD@LindaXYinMD and our stellar MS4 Cecelia Hidalgo for presenting our real world data with DART (30-36 Gy) for HPVOPC.
282 patients and 97% PFS for int risk group. DART is a standard tx for int risk pts @MayoCancerCare#ASTRO25
👏 Outstanding, balanced review by @MartinTomMD calling out #Vorasidenib hype in INDIGO (RCT of Vorasidenib vs Placebo for low grade glioma (LGG) patients with gross disease (i.e. high-risk LGG)
INDIGO data (IDH-mut LGG):
▶️ORR: 0% CR, 1% PR, 10% MR, 83% SD
▶️23% grade ≥3 tox (mostly ↑ LFTs)
▶️Never compared to RT+PCV/TMZ - only placebo
▶️Cross-over allowed (placebo patients were deprived standard of therapy chemoRT twice [at randomization, and at progression]
▶️82% placebo patients progressed at 2 years (these patients should NOT have been observed in the first place)
▶️Short follow-up (14 mo.)
RT toxicities in LGGs often overstated, especially in the context of modern RT techniques (IMRT, VMAT, protons):
🔷️Radiation necrosis ~2%
🔷️Absolute risk of stroke is exceedingly low
🔷️Hormone dysfunction only with significant hypothalamic/pituitary dose (and is a fixable issue); uncommon with modern conformal RT
🔷️Prospective cognitive studies: most show no sustained decline; when seen, often due to tumor progression, not RT
👉 Painting RT as a toxic treatment for LGGs while overselling modest to negligible INDIGO results is misleading for patients and physicians
#ASTRO25 #RadOnc #NeuroOnc
My mentee and future pediatric radonc leader Dr McKone’s fantastic presentation demonstrating improved targeting and risk stratification for pediatric neuroblastoma #ASTRO25@MayoRadOnc@MayoCancerCare
I am not aware of any better speakers on the topic of GI radiation oncology than @KrishanJethwa. Everything just becomes crystal clear. This is why you want to attend @MayoCancerCare CME courses in heme/onc. Quality updates for practitioners. @MayoHemeOnc
We are so grateful to have the leadership of @n_laack who’s vegetarian and traditional Hotdish game is on point! I am very🍀to be part of this program and astounded I just celebrated 10 years at @MayoRadOnc!